Status:
UNKNOWN
Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19
Lead Sponsor:
South Valley University
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general man...
Detailed Description
150 patient with early covid is devided into two groups first group will receive regular protocol of drugs second group will receive ivermectin nasal spray in addition to regular protocl of drugs
Eligibility Criteria
Inclusion
- early covid19 pateints
Exclusion
- children and pregnant women
Key Trial Info
Start Date :
January 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 20 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04716569
Start Date
January 20 2021
End Date
March 20 2021
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zaky Aref
Qina, Qena Governorate, Egypt, 83511